Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Postural Orthostatic Tachycardia Syndrome 1Multiple Myeloma 1Mastocytosis 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Bronchopulmonary Disease 1

Interventions

venetoclax 14ibrutinib 11Rituximab 9obinutuzumab 8Specimen Handling 7Cyclophosphamide 7acalabrutinib 6Biopsy 6zanubrutinib 5pirtobrutinib 5fludarabine phosphate 4Lenalidomide 4ARQ531 4idelalisib 3Whole-Body Irradiation 3Magnetic Resonance Spectroscopy 3Cyclosporine 3fludarabine 2Vincristine 2Sirolimus 2Prednisone 2Mycophenolic Acid 2Doxorubicin 2CT-P10 2Bendamustine Hydrochloride 2treosulfan 1tocilizumab 1pembrolizumab 1mirdametinib 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Mass Screening × 30 days × Clear all
NCT05844033 2026-05-19

Biomarker for Infection Risk in CLL and MM

Massachusetts General Hospital

Active not recruiting
150 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡